• Basilea reported Cresemba in-market sales of USD 817 million for July 2025-June 2026, up 25% year over year.
• Fosmanogepix phase 3 studies are ongoing in invasive candidiasis and invasive mold infections.
• Ceftibuten-ledaborbactam's phase 2/3 program in complicated urinary tract infections is scheduled to start in mid-2027.
• Zevtera's US market exclusivity runs until April 2034, supporting its long-term growth opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.